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ABSTRACT Recent Zika virus (ZIKV) outbreaks and unexpected clinical manifesta-
tions of ZIKV infection have prompted an increase in ZIKV-related research. Here, we
identify two strain-specific determinants of ZIKV virulence in mice. We found that
strain H/PF/2013 caused 100% lethality in Ifnar1/ mice, whereas PRVABC59 caused
no lethality; both strains caused 100% lethality in Ifnar1/ Ifngr1/ double-
knockout (DKO) mice. Deep sequencing revealed a high-frequency variant in PRV-
ABC59 not present in H/PF/2013: a G-to-T change at nucleotide 1965 producing a
Val-to-Leu substitution at position 330 of the viral envelope (E) protein. We show
that the V330 variant is lethal on both virus strain backgrounds, whereas the L330
variant is attenuating only on the PRVABC59 background. These results identify a
balanced polymorphism in the E protein that is sufficient to attenuate the PRVABC59
strain but not H/PF/2013. The consensus sequences of H/PF/2013 and PRVABC59 dif-
fer by 3 amino acids, but these were not responsible for the difference in virulence
between the two strains. H/PF/2013 and PRVABC59 differ by an additional 31 non-
coding or silent nucleotide changes. We made a panel of chimeric viruses with iden-
tical amino acid sequences but nucleotide sequences derived from H/PF/2013 or
PRVABC59. We found that 6 nucleotide differences in the 3= quarter of the H/PF/
2013 genome were sufficient to confer virulence in Ifnar1/ mice. Altogether, our
work identifies a large and previously unreported difference in virulence between
two commonly used ZIKV strains, in two widely used mouse models of ZIKV patho-
genesis (Ifnar1/ and Ifnar1/ Ifngr1/ DKO mice).
IMPORTANCE Contemporary ZIKV strains are closely related and often used inter-
changeably in laboratory research. Here, we identify two strain-specific determinants
of ZIKV virulence that are evident in only Ifnar1/ mice but not Ifnar1/ Ifngr1/
DKO mice. These results identify a balanced polymorphism in the E protein that is
sufficient to attenuate the PRVABC59 strain but not H/PF/2013. We further identify a
second virulence determinant in the H/PF/2013 strain, which is driven by the viral
nucleotide sequence but not the amino acid sequence. Altogether, our work identi-
fies a large and previously unreported difference in virulence between two com-
monly used ZIKV strains, in two widely used mouse models of ZIKV pathogenesis.
Our results highlight that even very closely related virus strains can produce signifi-
cantly different pathogenic phenotypes in common laboratory models.
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Zika virus (ZIKV) is a mosquito-transmitted flavivirus belonging to the Flaviviridaefamily of positive-sense single-stranded RNA viruses. ZIKV is related to other
pathogenic flaviviruses, including dengue virus (DENV), yellow fever virus (YFV), West
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Nile virus (WNV), Japanese encephalitis virus (JEV), and tick-borne encephalitis virus 
(TBEV). Historically, ZIKV has been associated with a self-limiting rash and febrile illness 
that resolves within a few days, and these symptoms occur in only 20% of infected 
individuals (1, 2). However, new clinical manifestations associated with recent ZIKV 
outbreaks, including Guillain-Barré syndrome and congenital Zika syndrome, have 
stimulated a surge in ZIKV research (2–5).
Since the spread of ZIKV to the Western Hemisphere, numerous ZIKV strains have 
been isolated from patients and mosquitoes and distributed to laboratories across the 
world. Some widely used strains include FSS13025, which was isolated in 2010 from 
patient serum in Cambodia; H/PF/2013, which was isolated in 2013 from patient serum 
in French Polynesia; PRVABC59, which was isolated in 2015 from patient serum in 
Puerto Rico; Paraiba_01/2015, which was isolated in 2015 from patient serum in Brazil; 
and Mex-2-81, which was isolated in 2016 from an Aedes mosquito in Mexico (6–9). All 
of these strains share high nucleotide identity (at least 98.6% identity between any two 
strains) and minimal amino acid differences throughout their genomes. Thus, these 
closely related contemporary strains have been used largely interchangeably, and 
results from studies using various strains have been compared and combined to draw 
overall conclusions about the pathogenesis of contemporary ZIKV strains. Furthermore, 
various immunodeficient mouse models are used to study ZIKV pathogenesis, and the 
two most commonly used systems (Ifnar1/ mice and Ifnar1/ Ifngr1/ double-
knockout [DKO] mice) largely have been assumed to yield comparable results. Ifnar1/ 
mice lack the type I interferon alpha/beta (IFN-/) receptor and are thus deficient in 
a key component of the innate antiviral response and highly susceptible to viral 
infections. Ifnar1/ Ifngr1/ DKO mice lack both the type I IFN-/ receptor as well 
as the type II IFN- receptor and consequently are even more immunocompromised 
than Ifnar1/ mice.
In this study, we identified two strain-specific determinants of ZIKV virulence that 
are evident in only Ifnar1/ mice but not Ifnar1/ Ifngr1/ DKO mice. We identified 
a balanced polymorphism in the E protein that is sufficient to attenuate the PRVABC59 
strain but not H/PF/2013. Furthermore, we identified a second virulence determinant in 
the H/PF/2013 strain that is driven by the viral nucleotide sequence and not the amino 
acid sequence.
RESULTS
ZIKV strains H/PF/2013 and PRVABC59 have distinct lethality phenotypes in 
Ifnar1/ mice. ZIKV strain H/PF/2013 was isolated from patient serum from a 2013 
outbreak in French Polynesia, and ZIKV strain PRVABC59 was isolated from patient 
serum from a 2015 outbreak in Puerto Rico (7, 8). Deposited consensus sequences for 
these ZIKV strains (GenBank accession numbers KJ776791 and KU501215) as well as 
Sanger sequencing of our laboratory stocks of H/PF/2013 and PRVABC59 (10, 11) show 
that these two strains are very similar: they share 99% nucleotide identity (34 
nucleotide differences across the genome) and have only 3 amino acid differences (1 
in capsid and 2 in nonstructural protein 5 [NS5]). Both strains have been used widely 
and largely interchangeably by many research groups studying ZIKV virology and 
pathogenesis (10–19). However, we found that H/PF/2013 and PRVABC59 have distinct 
lethality phenotypes in Ifnar1/ mice (Fig. 1). We infected 5- to 6-week-old Ifnar1/ 
mice with 1  103 focus-forming units (FFU) of ZIKV H/PF/2013 or PRVABC59 by a 
subcutaneous route in the footpad and evaluated weight loss and lethality (Fig. 1A and 
B). These experiments used isolate virus stocks, originally derived from patient serum 
samples propagated through several passages on Vero cells. ZIKV H/PF/2013 was lethal 
in Ifnar1/ mice, with mice beginning to lose weight at 6 days postinfection (dpi) and 
all mice succumbing by 11 dpi. In contrast, PRVABC59 was attenuated, causing no 
morbidity or mortality.
The attenuation of PRVABC59 was unexpected given its high similarity to H/PF/2013 
and because other groups have shown the PRVABC59 isolate to be lethal in Ifnar1/ 
Ifngr1/ DKO mice (19, 20). To test this, we infected 5- to 6-week-old Ifnar1/
FIG 1 PRVABC59 is attenuated in Ifnar1/ mice. Five- to six-week-old Ifnar1/, Ifnar1/ Ifngr1/ DKO, or
Ifng/ mice were inoculated with 1  103 (A to D) or 1  105 (E and F) FFU of ZIKV strain PRVABC59 or H/PF/2013
isolate viruses by a subcutaneous route. Mice were weighed daily for 14 days, and weights are expressed as
percentages of body weight prior to infection and were censored once one mouse in a group died. Results shown
are the mean values  standard errors of the means (SEM) for the indicated number of mice from one (E and F)
or two (A to D) independent experiments. Lethality was monitored for 21 days. †, the mouse died at 20 dpi.
Ifngr1/ DKO mice, as well as Ifng/ mice, with 1  103 FFU of PRVABC59 or 
H/PF/2013 isolate virus by a subcutaneous route in the footpad and evaluated weight 
loss and lethality (Fig. 1C and D). Ifnar1/  Ifngr1/ mice began losing weight at 
5 dpi, and all mice succumbed to either H/PF/2013 or PRVABC59 virus infection by 
10 dpi. These results indicate that despite its attenuation in Ifnar1/ mice, the PRV-
ABC59 isolate can be lethal in a more susceptible mouse model (mice lacking both 
IFN-/ and IFN- signaling). Unsurprisingly, since Ifng/ mice retain IFN-/ signal-
ing, no Ifng/ mice lost weight or succumbed to either virus, showing that the loss of 
IFN- signaling is not sufficient to render mice susceptible to ZIKV. To test whether 
PRVABC59 attenuation in Ifnar1/ mice could be overcome with a higher inoculation 
dose, we infected 5- to 6-week-old Ifnar1/ mice with 1  105 FFU of PRVABC59 
isolate virus by a subcutaneous route in the footpad and evaluated weight loss and 
lethality (Fig. 1E and F). Mice began losing weight at 5 dpi, but 5 of 7 mice recovered. 
One mouse began losing weight at 5 dpi and continued to lose weight until it 
succumbed at 11 dpi, while another mouse lost weight from 5 to 9 dpi; began to 
recover, gaining weight until 16 dpi; and then succumbed at 20 dpi. Thus, even at a
FIG 2 The PRVABC59 isolate contains high-frequency variants. (A and B) Deep sequencing was performed on ZIKV strains PRVABC59 and H/PF/2013. The cutoff
for single nucleotide polymorphisms was set at a depth of 10 reads and a mutation rate of 3% (black dashed lines). The gray dashed line indicates a 10%
mutation rate. (C and D) Primer ID was performed on ZIKV strains PRVABC59 and H/PF/2013 for the indicated 483-nucleotide region (red line under the
full-genome sequence) covering amino acids 231 to 392 of the envelope protein.
100-fold-higher inoculation dose, the PRVABC59 isolate virus did not cause the 100%
lethality characteristic of the H/PF/2013 strain in Ifnar1/ mice. Altogether, these data 
reveal profoundly different virulence phenotypes between ZIKV strains PRVABC59 and 
H/PF/2013 in Ifnar1/ mice despite their similar phenotypes in Ifnar1/ Ifngr1/ 
DKO mice. Given the high genetic similarity between PRVABC59 and H/PF/2013, we 
further investigated the viral determinants of these distinct virulence phenotypes.
The PRVABC59 isolate contains high-frequency variants. Although the consen-
sus sequences of PRVABC59 and H/PF/2013 were highly similar, isolate viruses typically 
contain a mixture of genetic variants either present in the original patient sample or 
generated during passage in cell culture. To determine whether these two strains 
included distinct variants compared to their reference genomes, we sequenced RNA 
isolated from concentrated virus stocks using a deep-sequencing protocol. Most of the 
variants found in the two virus strains were present at relatively low frequencies 
(10%), with the variants distributed across the genome. However, the PRVABC59 
isolate contained 10 variants at a 10% frequency, whereas H/PF/2013 contained 1 
variant at a 10% frequency, which was not shared between the two viruses (Fig. 2A 
and B). The PRVABC59 variant present at the highest frequency was a G-to-T mutation
TABLE 1 Percent variation at nucleotide 1965 of viruses grown in Vero or C6/36 cells
Virus GenBank accession no. Cell line % T (Leu)a % G (Val) residues
H/PF/2013 KJ776791 Vero 0 100
C6/36 0 100
PRVABC59 KU501215 Vero 69 31
C6/36 72 28
Paraiba KX280026 Vero 0 100
C6/36 0 100
FSS13025 KU955593 Vero 0 100
C6/36 0 100
Mex-2-81 KX446950 Vero 0 100
C6/36 0 100
Dakar 41662 KU955592.1 Vero 0 100
C6/36 0 100
Dakar 41671 KU955595.1 Vero 0 100
C6/36 0 100
DENV4 KU513442.1 Vero 0 100
C6/36 0 100
SPOV KX227370.1 Vero 100 (CTG) 0
C6/36 100 (CTG) 0
aThe Leu codon for ZIKV is TTA, and that for SPOV is CTG.
at nucleotide 1965, resulting in a Val-to-Leu substitution at amino acid position 330 in 
domain III of the envelope protein. These data are consistent with deep-sequencing 
results for the PRVABC59 strain from other groups, who also identified the V330L 
substitution (19–21), suggesting that this polymorphism is maintained through inde-
pendent passages of this strain in separate laboratories. To quantify more accurately 
the frequency of G1965T variation in ZIKV stocks, we next used the Primer ID sequenc-
ing strategy. Primer ID is a deep-sequencing technique that incorporates an 11-
nucleotide degenerative index into the cDNA synthesis primer, thereby uniquely 
identifying each template sequence and allowing resampled sequencing reads to be 
identified and pooled to create a highly accurate consensus sequence for each tem-
plate (22). Primer ID confirmed an 70% frequency of the G1965T variant in the 
PRVABC59 isolate, whereas no variation was detected at position 1965 of strain 
H/PF/2013 (Fig. 2C and D). To investigate whether this variant was unique to ZIKV strain 
PRVABC59, we performed Primer ID on seven ZIKV strains propagated in either Vero or 
C6/36 cells, including two African-lineage strains (Dakar 41662 and Dakar 41671) and 
five Asian-lineage strains (H/PF/2013, PRVABC59, FSS13025, Paraiba_01/2015, and Mex-
2-81). We also tested two related flaviviruses, Spondweni virus (SPOV) and DENV (Table 
1). The published consensus sequences for all of these viruses encode a Val at position 
330, except for SPOV, which encodes a Leu. We found that only the PRVABC59 strain 
has variation at position 1965 in virus grown in either Vero (69% T) or C6/36 (72% T) 
cells. These results indicate that the PRVABC59 isolate maintains T/G variation at 
position 1965 of the genome through multiple independent passages, suggesting a 
balanced polymorphism that is not found in other ZIKV strains or in either of two 
related flaviviruses. Next, we asked whether this variant was responsible for attenuating 
the PRVABC59 isolate in Ifnar1/ mice.
PRVABC59 V330 is lethal in Ifnar1/ mice, whereas L330 is attenuated. To test 
whether the G/T1965 variant affected ZIKV virulence, we generated infectious clones of 
PRVABC59 or H/PF/2013 with either a G at position 1965 (V330) or a T at position 1965 
(L330) of the genome (Table 2). We evaluated the replication of the PRVABC59 and 
H/PF/2013 isolates, L330, and V330 viruses in Vero, A549, and C6/36 cells and did not
TABLE 2 ZIKV infectious clones, mutants, and chimeras generated from the PRVABC59 or




(nt change) % lethalityd
MTD
(days)dA B C D
H/PF/2013 V330 PF PF PF PF Consensus 100 6.6
H/PF/2013 L330 PF PF PF PF V330L (G1965T) 100 6.7
PRVABC59 V330 PRV PRV PRV PRV Consensus 100 8.6
PRVABC59 L330 PRV PRV PRV PRV V330L (G1965T) 10 15.0




V024 PRV PRV PF PF I75T (C346T) 70 12.4
V330L (G1965T)
V025 PF PF PRV PRV V330L (G1965T) 0 None
V37A (T7939C)
V60M (G8007A)
V026 PRV PRV PF PRV I75T (C346T) 20 13.5
V330L (G1965T)




aPRV, PRVABC59; PF, H/PF/2013.
bAmino acid (aa) numbering is for individual proteins (C, E, or NS5), and nucleotide (nt) numbering is for the 
complete genome.
cI75T is in C, V330L is in E, and V2611A and V2634M are in NS5.
dPercent lethality and mean time to death (MTD) determined in Ifnar1/ mice.
find uniform differences (Fig. 3). Although there were statistically significant differences 
between the V330 and L330 viruses in some cell types, the magnitude of these 
differences was less than 10-fold, and the direction was inconsistent (PRVABC59 L330 
greater than V330 in Vero and C6/36 cells; V330 greater than L330 in A549 cells for both 
backgrounds). These results indicate that V330L variation does not dramatically impact 
ZIKV replication in cell culture.
To evaluate virulence, we infected 5- to 6-week-old Ifnar1/ mice with 1  103 FFU 
of PRVABC59 or H/PF/2013 V330 or L330 clone virus by a subcutaneous route in the 
footpad and evaluated weight loss and lethality (Fig. 4). Mice infected with PRVABC59 
L330 lost weight from 6 to 9 dpi, with only 1 of 7 mice succumbing, whereas mice 
infected with PRVABC59 V330 virus began losing weight at 6 dpi, and all mice suc-
cumbed by 11 dpi (Fig. 4A and B). All mice infected with either the H/PF/2013 V330 or 
L330 virus began losing weight at 6 dpi and succumbed by 8 dpi (Fig. 4C and D). To 
determine whether the PRVABC59 L330 virus could be lethal in a more susceptible 
mouse model, we infected 8-week-old Ifnar1/ Ifngr1/ DKO mice with 1  103 FFU 
by a subcutaneous route in the footpad. Mice began to lose weight at 4 dpi, and all 
mice succumbed by 10 dpi (Fig. 4A and B). These results show that the L330 variant is 
attenuating on the PRVABC59 genetic background (with a phenotype similar to that of 
the PRVABC59 isolate virus) but did not impact virulence on the H/PF/2013 genetic 
background, altogether implying an epistatic effect of L330 on virulence.
Since the PRVABC59 V330 and L330 viruses produced distinct lethality phenotypes 
in Ifnar1/ mice, we next compared viral loads in serum and tissues (Fig. 5). We 
infected 5- to 6-week-old Ifnar1/ mice with 1  103 FFU of the PRVABC59 V330 or 
L330 virus by a subcutaneous route in the footpad and measured viral loads in serum 
at 2, 4, and 6 dpi (Fig. 5A) and viral loads in tissues (spleen, brain, eyes, and testes) at 
6 dpi by quantitative reverse transcription-PCR (qRT-PCR) (Fig. 5B to E). Compared to 
the V330 virus, the L330 virus produced similar viral loads at 2 and 4 dpi but signifi-
cantly lower viral loads at 6 dpi in serum (10-fold reduction). There was no significant 
difference between the PRVABC59 V330 and L330 viral loads in any tissues tested at 
6 dpi. However, at 6 dpi, mice infected with either the V330 or L330 virus exhibited
FIG 3 The V330L substitution does not uniformly impact ZIKV replication in cell culture. Vero (A and D), A549 (B and E), or C6/36
(C and F) cells were infected with ZIKV PRVABC59 or H/PF/2013 isolate, V330 clone, or L330 clone virus at an MOI of 0.01. Viruses in
culture supernatants were titrated by a focus-forming assay. Data shown are the mean values  SEM for 9 samples from 3
independent experiments. V330 and L330 viruses were compared to each other by 2-way ANOVA with multiple comparisons. **,
P  0.01; ***, P  0.001; ****, P  0.0001.
minimal morbidity. To evaluate viral loads at a time point with a distinct disease 
presentation, we infected Ifnar1/ mice as described above but harvested tissues at 
8 or 9 dpi, when all V330-infected mice exhibited disease signs constituting a humane 
endpoint and L330-infected mice exhibited no overt disease signs. One PRVABC59 
V330-infected mouse was moribund and harvested at 8 dpi, and all other V330-infected 
mice were moribund and harvested at 9 dpi, along with all L330-infected mice. We 
measured viral loads in the brain by qRT-PCR (Fig. 5F). Mice infected with the PRVABC59 
L330 virus had significantly lower viral loads in the brain than did V330-infected mice 
at 8 to 9 dpi. Sanger sequencing of viruses isolated from the brains of infected mice 
confirmed that the viruses maintained their original V330 or L330 genotype, with no 
additional mutations in E. The lower viral loads in the brains of L330-infected mice are 
consistent with the attenuated phenotype of this virus and, combined with lower 
viremia at 6 dpi, suggest a more efficient clearance of the L330 virus than of V330. We 
considered whether a higher genome/FFU ratio for the L330 virus might result in 
enhanced immune stimulation and more rapid clearance. However, we found that the 
genome/FFU ratio of the PRVABC59 L330 virus stock was similar to that of the V330 
virus (213 versus 450).
Nucleotide differences near the 3= end of the H/PF/2013 genome confer le-
thality. Since the variation at position 330 of the envelope protein affected virulence 
only on the PRVABC59 background and not on the H/PF/2013 background, other 
differences between the two viruses must contribute to virulence in Ifnar1/ mice. The 
consensus sequences of PRVABC59 and H/PF/2013 differ by only 34 nucleotides 
throughout the genome. These include 30 silent changes, 1 noncoding change, and 3 
coding changes (one in capsid [I/T75] and two in the methyltransferase domain of NS5 
[V/A37 and V/M60]). To test whether any of the 3 amino acids that differ between the 
two viruses were responsible for their differential lethality in Ifnar1/ mice, we used 
site-directed mutagenesis to generate a PRVABC59 L330 virus (V020) with an amino
FIG 4 The V330L substitution is attenuating on a PRVABC59 but not on an H/PF/2013 background in 
Ifnar1/ mice. Five- to six-week-old Ifnar1/ mice or 8-week-old Ifnar1/ Ifngr1/ DKO mice were 
inoculated with 1  103 FFU of ZIKV strain PRVABC59 or H/PF/2013 V330 or L330 viruses by a subcuta-
neous route. (A and C) Mice were weighed daily for 14 days. Weights are expressed as percentages of 
body weight prior to infection and were censored once one mouse in a group died. (B and D) Lethality 
was monitored for 21 days. Results shown are the means  SEM for 11 to 14 Ifnar1/ mice (PRVABC59 
V330 and L330) and 9 Ifnar1/ mice (H/PF/2013 V330 and L330) from two independent experiments or 
8 Ifnar1/ Ifngr1/ DKO mice from one experiment.
acid sequence identical to that of H/PF/2013 L330 but maintaining the 31 silent and 
noncoding nucleotides from the PRVABC59 genome (Table 2 and Fig. 6A). We com-
pared the replication of V020 to that of PRVABC59 L330 in Vero cells, and while there 
were statistically significant differences in viral titers, the magnitude of the difference 
was small (greatest difference, 4-fold). Thus, we concluded that V020 was not 
markedly impaired in replication in Vero cells (Fig. 6B). We infected 5- to 6-week-old 
Ifnar1/ mice with 1  103 FFU of PRVABC59 L330 or V020 by a subcutaneous route 
in the footpad and evaluated weight loss and lethality (Fig. 6C and D). Mice infected 
with PRVABC59 L330 began losing weight from 7 to 10 dpi, with only 1 of 7 mice 
succumbing to the infection, similar to previous experiments (Fig. 4). Mice infected with 
V020 did not lose weight, and no mice succumbed to the infection. These results 
indicate that the 3 amino acids that differ between the consensus sequences of the 
PRVABC59 and H/PF/2013 viruses are not responsible for their differential lethality in 
Ifnar1/ mice.
Since amino acid changes did not explain the observed differences in virulence 
between the PRVABC59 L330 and H/PF/2013 L330 viruses, we next investigated 
whether the remaining 31 nucleotide differences between the two strains were re-
sponsible. The infectious clone system used to generate PRVABC59 and H/PF/2013 
viruses divides the viral genome over four plasmids (fragments A, B, C, and D) (10, 11). 
The high sequence identity between PRVABC59 and H/PF/2013 preserves the restric-
tion sites used to ligate each genomic fragment, making it straightforward to generate 
chimeras of the two strains. We generated chimeric viruses encoding the PRVABC59 
L330 amino acid sequence but the nucleotide sequence of either PRVABC59 or H/PF/ 
2013 and evaluated their virulence in Ifnar1/ mice (Table 2 and Fig. 7A). All chimeric 
viruses tested replicated equivalently to the wild-type (WT) L330 virus in Vero cells, 
except for V024, which had significantly lower titers at 24 or 48 h (Fig. 7B). We first 
tested viruses with the 5= half (fragments A and B) derived from the PRVABC59
FIG 5 PRVABC59 L330 produces low viral loads late in infection. Five- to six-week-old Ifnar1/ mice were 
inoculated with 1  103 FFU of ZIKV strain PRVABC59 V330 or L330 virus by a subcutaneous route in the 
footpad. (A) Blood was collected 2, 4, and 6 days after infection, and ZIKV RNA in serum was measured 
by qRT-PCR. (B to E) Mice were euthanized 6 days after infection and perfused, and tissues were 
harvested. ZIKV RNA in tissue was measured by qRT-PCR. (F) V330-infected mice were euthanized when 
they reached a humane endpoint (8 or 9 dpi) and L330-infected mice were euthanized at 9 dpi, tissues 
were harvested, and ZIKV RNA in the brain was measured by qRT-PCR. ****, P  0.0001 (unpaired 2-tailed 
t test). Results shown represent data from 2 independent experiments.
nucleotide sequence and the 3= half (fragments C and D) derived from the H/PF/2013 
nucleotide sequence (V024) or vice versa (V025) (Fig. 7A). We infected 5- to 6-week-old 
Ifnar1/ mice with 1  103 FFU of V024 or V025 virus by a subcutaneous route in the 
footpad and evaluated weight loss and lethality (Fig. 7C and D). Mice infected with 
V024 began losing weight at 7 dpi, and 6 of 8 mice succumbed to the virus by 11 dpi, 
whereas mice infected with V025 did not lose weight, and no mice succumbed to the 
virus. Since both viruses encoded the same amino acid sequence, these data indicate 
that nucleotides on the 3= half of the H/PF/2013 genome confer virulence in Ifnar1/ 
mice. To further define which of these 19 nucleotide differences contribute to the 
virulent phenotype, we generated chimeric viruses still encoding the PRVABC59 L330 
amino acid sequence but with either the C fragment (V026) or D fragment (V027) 
having the nucleotide sequence of H/PF/2013. The C fragment contains 13 nucleotide 
differences between the two strains, and the D fragment contains 6. We infected 5- to 
6-week-old Ifnar1/ mice with 1  103 FFU of V026 or V027 virus by a subcutaneous 
route in the footpad and evaluated weight loss and lethality (Fig. 7E and F). Mice 
infected with V026 lost weight from 6 to 12 dpi, with 7 of 9 mice recovering, whereas 
mice infected with V027 began losing weight at 6 dpi, and all mice succumbed to the 
virus by 11 dpi. To test if the increased virulence of V027 corresponded to higher viral 
loads, we infected 5- to 6-week-old Ifnar1/ mice with 1  103 FFU of V026 or V027 
virus by a subcutaneous route in the footpad and harvested tissues to measure ZIKV 
RNA by qRT-PCR (Fig. 7G). V027-infected mice were euthanized at 9 dpi, when the mice 
exhibited disease signs constituting a humane endpoint. Tissues from V026-infected
FIG 6 Three amino acids that differ between H/PF/2013 and PRVABC59 do not confer lethality. (A) Schematic of the PRVABC59 L330
and V020 genomes depicting the introduction of 3 H/PF/2013 amino acids (I75 in C and A37 and M60 in NS5) on the PRVABC59 L330
background; small circles indicate nucleotide differences between PRVABC59 and H/PF/2013. (B) Vero cells were infected with ZIKV
PRVABC59 L330 or V020 at an MOI of 0.01. Viruses in culture supernatants were titrated by a focus-forming assay. Data shown are the
means  SEM for 9 samples from 3 independent experiments. *, P  0.05; ****, P  0.0001 (2-way ANOVA with multiple comparisons).
(C and D) Five- to six-week-old Ifnar1/ mice were inoculated with 1  103 FFU of ZIKV strain PRVABC59 L330 or V020 virus by a
subcutaneous route. Mice were weighed daily for 14 days, and weights are expressed as percentages of body weight prior to infection
and were censored once one mouse in a group died. Results shown are the mean values  SEM for 7 mice for PRVABC59 L330 and
11 mice for V020 from four independent experiments. Lethality was monitored for 21 days.
mice were harvested at the same time, although these mice did not exhibit severe 
disease signs. Brain viral loads in V027-infected mice were significantly higher (10-fold) 
than those in V026-infected mice at 9 dpi, consistent with the greater virulence of the 
V027 virus. Sanger sequencing of viruses isolated from the brains of infected mice 
confirmed that the viruses maintained the 6 nucleotides that differ in the D fragment, 
with no additional mutations. These data suggest that the 6 nucleotides that differ 
between the two viruses on the D fragment are sufficient to confer the virulent 
phenotype of the H/PF/2013 strain.
Altogether, this work identifies a large and previously unreported difference in 
virulence between two commonly used ZIKV strains. Our data further define the effect 
of a previously reported variant in the PRVABC59 strain. We also identify a novel role for 
noncoding changes as ZIKV virulence determinants, suggesting possible effects on RNA 
properties such as RNA structure or posttranscriptional modifications.
DISCUSSION
The new clinical manifestations associated with ZIKV after its emergence in the 
Western Hemisphere, particularly congenital Zika syndrome, led to a surge in ZIKV 
research. Many different ZIKV strains have been isolated during recent outbreaks and 
distributed to research laboratories around the world (e.g., 12 contemporary strains 
available from BEI Resources and 20 from the World Reference Center for Emerging 
Viruses and Arboviruses). All contemporary ZIKV strains share high nucleotide identity 
and minimal amino acid differences throughout their genomes and thus have been 
used largely interchangeably to draw conclusions about the pathogenesis of contem-
porary ZIKV strains. However, not all contemporary ZIKV strains share the same patho-
genic outcome in mice. Both a ZIKV strain isolated in 2013 from French Polynesia 
(H/PF/2013) and a strain isolated in 2015 from Brazil (Paraiba_01/2015) have been 
shown to cause 100% lethality in Ifnar1/ mice (23, 24). In contrast, a ZIKV strain 
isolated in 2010 from Cambodia (FSS13025) was only 20 to 30% lethal in Stat2/ or 
Ifnar1/ mice, and a strain isolated in 2015 from Puerto Rico (PRVABC59) was not 
lethal in either mouse model (25). However, the H/PF/2013, FSS13025, and PRVABC59
FIG 7 Nucleotides at the 3= end of ZIKV strain H/PF/2013 confer lethality in mice. (A) Schematic of PRVABC59 and H/PF/2013 chimeric
viruses (V024 to V027). Brown circles depict the introduction of 3 H/PF/2013 amino acids; small circles indicate nucleotide differences
between PRVABC59 and H/PF/2013. (B) Vero cells were infected with ZIKV H/PF/2013 L330, V024, V025, V026, or V027 at an MOI of 0.01.
Viruses in culture supernatants were titrated by a focus-forming assay. Data shown are the means  SEM for 9 samples from 3
independent experiments. **, P  0.01; ***, P  0.001 (2-way ANOVA). (C to G) Five- to six-week-old Ifnar1/ mice were inoculated with
1  103 FFU of ZIKV V024, V025, V026, or V027 by a subcutaneous route. Mice were weighed daily for 21 days, and weights are expressed
as percentages of body weight prior to infection and were censored once one mouse in a group died. Results shown are the mean
values  SEM for the indicated numbers of Ifnar1/ mice for each virus from three independent experiments. Lethality was monitored
for 21 days. (G) Mice were euthanized 9 days after infection, and tissues were harvested. ZIKV RNA in the brain was measured by qRT-PCR.
*, P  0.05 (unpaired 2-tailed t test).
strains were uniformly lethal in Ifnar1/ Ifngr1/ DKO mice (19, 20, 26, 27). These 
data indicate ZIKV strain-specific contributions to virulence in mice and highlight that 
differences in pathogenesis may not be evident in highly susceptible models, such as 
Ifnar1/ Ifngr1/ DKO mice, or in younger mice. Strain characteristics such as virus 
source (human versus mosquito), disease outcome, geographic origin, or year of 
isolation do not obviously correlate with the pathogenic phenotype in mice, although 
such relationships might be revealed by comparing a larger number of strains under 
identical experimental conditions (23, 25, 28). ZIKV lethality is also age dependent, with 
younger mice being more susceptible than older mice (29). Accordingly, Manan-
geeswaran et al. found that neonatal (10-day-old) Ifnar1/ mice were susceptible to 
the PRVABC59 isolate (12), whereas the 5- to 6-week old Ifnar1/ mice used in our 
experiments were not. In this study, we describe two distinct genetic determinants of 
ZIKV strain-specific virulence; notably, both phenotypes were evident in Ifnar1/ mice 
but masked in Ifnar1/ Ifngr1/ DKO mice. Our results further define the effect of a 
previously reported variant in the PRVABC59 strain (19), identify a novel role for 
noncoding changes as ZIKV virulence determinants, and highlight that even very 
closely related virus strains can produce significantly different pathogenic phenotypes 
in common laboratory models.
Duggal et al. previously reported variants in the PRVABC59 isolate virus that led to 
attenuated pathogenesis in Ifnar1/ Ifngr1/ DKO mice (19). Their deep sequencing 
revealed the presence of a Val-to-Leu substitution at position 330 of the E protein as 
well as a Trp-to-Gly substitution at position 98 of nonstructural protein 1 (NS1). Those 
authors concluded that the substitutions were tissue culture adaptations, as these 
variants were found at very low levels upon deep sequencing of the original patient 
sera and were found to increase in frequency over three passages in Vero cells. 
However, while these substitutions increased in frequency with passage, it is not clear 
whether they are truly adaptive. Notably, we did not detect the L330 substitution in the 
H/PF/2013 strain, even though our stock of this strain has been passaged more 
extensively in Vero cells than the PRVABC59 strain, nor was this substitution detected 
in other ZIKV strains that we tested (although many of these have less certain passage 
histories). Furthermore, the frequency of the V330 and L330 variants remains constant 
(70% L330) in independent passages of the PRVABC59 strain grown on different cell 
types (Vero versus C6/36) and by different laboratories. The stability of this variation 
could suggest a balanced polymorphism at this site, although the selective advantage 
of this or why it would be advantageous only on the PRVABC59 genetic background is 
unclear.
Duggal et al. found that the L330 substitution attenuated the virus in 12- to 
16-week-old Ifnar1/ Ifngr1/ DKO mice, increasing the mean time to death, and the 
addition of the NS1 G98 substitution further attenuated the virus, highlighting the 
ability of this variant to act epistatically to modulate virulence. We also identified 
the E L330 and NS1 G98 variants in our PRVABC59 isolate, which were not present in 
our H/PF/2013 stock. We found that the L330 substitution was sufficient to attenuate 
the PRVABC59 virus in Ifnar1/ mice (recapitulating the phenotype of the isolate 
virus), so we did not further investigate the NS1 G98 variant.
ZIKV replicates poorly in mice with intact IFN-/ signaling due to an inability to 
antagonize murine STAT2 and STING (30–33). Thus, mouse pathogenesis studies typi-
cally use mice deficient in IFN-/ signaling, and both Ifnar1/ and Ifnar1/ If-
ngr1/ DKO mice are widely used in the field (20, 23, 26, 27, 34, 35). However, 
Ifnar1/ Ifngr1/ DKO mice develop severe disease and succumb rapidly to ZIKV 
infection, independent of the inoculation route, compared to Ifnar1/ mice (26, 29). 
Consistent with the phenotype of the PRVABC59 isolate virus, our PRVABC59 L330 virus 
caused 100% lethality in Ifnar1/ Ifngr1/ DKO mice but only 10% lethality in 
Ifnar1/ mice.
We found that the L330 substitution was sufficient to attenuate virulence on the 
PRVABC59 genetic backbone (10% lethality with PRVABC59 L330, compared to 100%
lethality with PRVABC59 V330 in Ifnar1/ mice). So it was surprising that this same 
substitution had no effect on the H/PF/2013 backbone (the L330 virus remained 100%
lethal). The E protein facilitates membrane fusion between the virus and the host cell 
and is the primary viral protein against which neutralizing antibodies are produced 
(36–38). Flavivirus E proteins are class II fusion proteins with three distinct domains: 
domain I (EDI), domain II (EDII), and domain III (EDIII) (39). EDI and EDII are discontin-
uous, forming a central -barrel and an elongated dimerization region, respectively, 
while EDIII forms a continuous C-terminal, immunoglobulin-like domain. It is not 
obvious how a Val-to-Leu substitution in EDIII would attenuate virulence. Compared to 
the V330 virus, PRVABC59 L330 produced low viral loads in the serum at 6 dpi and in
the brain at 9 dpi, despite similar viral loads earlier in infection, suggesting that the 
L330 virus may be cleared more efficiently. However, why this would be specific to the 
PRVABC59 strain remains unclear. Apart from the V330L variation, the PRVABC59 and 
H/PF/2013 strains have identical E protein amino acid sequences, so the L330 substi-
tution would be expected to have a similar effect on both strains. An alternative 
explanation is that the distinct virulence phenotypes are determined not by the V330L 
change in the E protein but by the effect of the G1965T nucleotide change on RNA 
structure or other RNA functions. Unfortunately, the codons in this position preclude 
the generation of mutants that would distinguish the effects of nucleotide and amino 
acid changes at this site.
Since the L330 substitution was not attenuating on the H/PF/2013 background, and 
the other 3 amino acids that differ between the two strains did not have an effect on 
virulence, we sought to identify which of the other 31 nucleotide differences between 
the two strains were responsible for the differential lethality. Using chimeric viruses, we 
were able to narrow down the virulence determinant to 6 nucleotide differences in the 
3= region of the H/PF/2013 genome (including NS5 and the 3= untranslated region 
[UTR]), although the mechanism by which these nucleotide changes modulate viru-
lence remains unclear. Possible mechanisms could include effects on RNA structure 
and/or posttranscriptional modifications, although according to a Web server for 
predicted RNA secondary structure (https://rna.urmc.rochester.edu/RNAstructureWeb/
Servers/Fold/Fold.html), these changes did not obviously disrupt predicted RNA struc-
tures. These changes also did not correspond to reported long-range RNA interactions 
within the ZIKV genome (40, 41) or experimentally determined m6A modification sites 
(42). One of the nucleotide differences falls 6 nucleotides upstream of the first stem-
loop structure in the 3= UTR. Thus, it is plausible that one or more of the nucleotide 
changes between PRVABC59 and H/PF/2013 could impact the production, stability, or 
function of subgenomic flavivirus RNA (sfRNA). sfRNA is a stable RNA degradation 
product resulting from the stalling of the cellular 5=-to-3= exoribonuclease Xrn1 on RNA 
structures in the flavivirus 3= UTR, which has been shown to modulate the replication 
and virulence of ZIKV and other flaviviruses (43, 44).
Altogether, our work identifies a large and previously unreported difference in 
virulence between two commonly used ZIKV strains, in two widely used mouse models 
of ZIKV pathogenesis (Ifnar1/ and Ifnar1/ Ifngr1/ DKO mice). Our data further 
describe the effect of a previously reported variant in the PRVABC59 strain that appears 
to be attenuating only on the PRVABC59 genetic background. We also identified a 
novel role for noncoding changes as ZIKV virulence determinants, suggesting possible 
effects on RNA structure or posttranscriptional modifications. Our results highlight that 
even very closely related virus strains can produce significantly different pathogenic 
phenotypes in common laboratory models.
MATERIALS AND METHODS
Viruses and cells. ZIKV strains H/PF/2013 and PRVABC59 were provided by the U.S. Centers for 
Disease Control and Prevention (8, 45). ZIKV strains Dakar 41662, Dakar 41671, FSS13025, and Mex-2-81, 
as well as SPOV, were provided by the World Reference Center for Emerging Viruses and Arboviruses 
(6–8). ZIKV strain Paraiba_01/2015 was obtained from Michael Diamond (Washington University in St. 
Louis), and DENV4 was obtained from Aravinda de Silva (UNC) (9, 46). Virus stocks were grown in Vero 
(African green monkey kidney epithelial) cells. Titers of virus stocks were determined on Vero cells by a 
focus-forming assay (FFA) (47). Vero and A549 cells were maintained in Dulbecco’s modified Eagle 
medium (DMEM) containing 5% heat-inactivated fetal bovine serum (FBS) and L-glutamine at 37°C with 
5% CO2. C6/36 cells were maintained in DMEM containing 6% FBS, nonessential amino acids (NEAA), and 
penicillin-streptomycin (P/S) at 32°C with 5% CO2. For multistep growth analysis, cells were infected at 
a multiplicity of infection (MOI) of 0.01 and incubated at 37°C or 32°C with 5% CO2 for 1 h. Next, the 
inoculum was aspirated, cells were washed with phosphate-buffered saline (PBS), and the medium was 
replenished. Samples of the infected cell culture supernatant were collected at 4, 24, 48, and 72 h 
postinfection and stored at 80°C for virus titration. Virus quantification was performed by an FFA on 
Vero cells. Duplicates of serial 10-fold dilutions of virus in viral growth medium (DMEM containing 2% FBS 
and 20 mM HEPES) were applied to Vero cells in 96-well plates and incubated as described above for 1 h. 
Following virus adsorption, the monolayers were overlaid with 1% methylcellulose in Eagle minimum 
essential medium (MEM). Infected cell foci were detected 42 to 46 h after infection. Following fixation 
with 2% paraformaldehyde for 1 h at room temperate, plates were incubated with 500 ng/ml of flavivirus-
cross-reactive mouse monoclonal antibody (MAb) E60 (48) for 2 h at room temperature or overnight at 4°C. 
After incubation at room temperature for 2 h with a 1:5,000 dilution of horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG (Sigma), foci were detected by the addition of the TrueBlue substrate (KPL). 
Foci were quantified with an Immunospot analyzer (Cellular Technology Limited).
ZIKV infectious clone mutagenesis. We used previously described infectious clones of ZIKV strain 
H/PF/2013 or PRVABC59, generated using a quadripartite infectious clone system (10, 11). Due to the 
high sequence identity between H/PF/2013 and PRVABC59, the same naturally occurring class IIG 
nonpalindromic restriction endonuclease sites within the full-length genome were used for both 
infectious clones, allowing us to swap fragments between the two strains to generate chimeric viruses. 
PCR site-directed mutagenesis was used to introduce mutations into H/PF/2013 or PRVABC59 plasmids. 
The resulting purified plasmids were digested, ligated, in vitro transcribed, and electroporated into Vero 
or C6/36 cells as previously described (49). Supernatants from electroporated Vero or C6/36 cells were 
harvested after 6 to 7 days and passaged once on Vero cells to generate virus stocks. Virus stocks were 
titrated by an FFA on Vero cells. Restriction enzymes and the Phusion high-fidelity PCR kit were obtained 
from New England BioLabs. A SuperScript III first-strand synthesis kit was obtained from Invitrogen. 
Oligonucleotide primers and probes for DNA amplification and qRT-PCR and sequencing primers were 
obtained from Sigma and IDT. The mMachine T7 Ultra transcription kit was obtained from Ambion. 
Antiflavivirus monoclonal antibody E60 was produced by the UNC Protein Expression and Purification 
Core Facility (48). Secondary antibodies were obtained from Sigma.
Mouse experiments. Animal husbandry and experiments were performed under the approval of the 
University of North Carolina at Chapel Hill Institutional Animal Care and Use Committee. Five- to 
six-week-old, or 8-week-old, male and female Ifnar1/, Ifnar1/ Ifngr1/ DKO, or Ifng/ mice on a 
C57BL/6 background were used. Mice were inoculated with 1  103 or 1  105 FFU of ZIKV in a volume 
of 50 l by a subcutaneous route in the footpad. Survival and weight loss were monitored for 14 or 
21 days. Animals that lost 30% of their starting weight or that exhibited severe disease signs were 
euthanized. Weights are reported as percentages of weights on the day of infection, and group means 
were censored once one animal in a group died.
Measurement of viral burden. ZIKV-infected mice were sacrificed at 6 to 9 dpi and perfused with 
20 ml of PBS. Spleen, kidney, testes, brain, and eyes were harvested and homogenized with zirconia 
beads (BioSpec) in a MagNA Lyser instrument (Roche Life Science) in 500 l (eyes) or 1 ml (all other 
tissues) of RLT buffer (Qiagen). Blood was collected at 2 and 4 dpi by submandibular bleed with a 5-mm 
Goldenrod lancet and by cardiac puncture at 6 dpi. Blood was collected in serum separator tubes (BD), 
and serum was separated by centrifugation at 8,000 rpm for 5 min. Tissues and serum from infected 
animals were stored at 80°C until RNA isolation. Tissue samples and serum from ZIKV-infected mice 
were extracted with the RNeasy minikit (tissues) or viral RNA minikit (serum) (Qiagen). ZIKV RNA levels 
were determined by TaqMan one-step qRT-PCR on a CFX96 Touch real-time PCR detection system 
(Bio-Rad) under standard cycling conditions. The viral burden is expressed as genome copies per milliliter 
on a log10 scale after comparison with a standard curve produced using serial 100-fold dilutions of 
the ZIKV A plasmid. A previously reported primer set was used to detect ZIKV RNA: forward primer 
CCGCTGCCCAACACAAG, reverse primer CCACTAACGTTCTTTTGCAGACAT, and probe 5=-FAM (6-
carboxyfluorescein)-AGCCTACCT-ZEN-TGACAAGCAATCAGACACTCAA-3=IABkFQ (Integrated DNA Tech-
nologies) (11, 50).
Deep sequencing. Viruses were grown on Vero cells, virions were concentrated over a 20% sucrose 
cushion by ultracentrifugation, and full-length virion RNA was extracted using TRIzol (Ambion) according to 
the manufacturer’s protocol. PRVABC59 RNA was submitted to the UNC Chapel Hill Vironomics Core for library 
construction and sequencing on an Ion S5 instrument (Thermo Fisher Scientific). H/PF/2013 cDNA was made 
using extracted full-length virion RNA using random primer 9 (NEB) and SuperScript II, and the second strand 
of the cDNA was synthesized using the NEBNext Ultra II nondirectional RNA second-strand synthesis module 
(NEB) according to the manufacturer’s suggested protocol. Libraries were constructed from this double-
stranded cDNA using a Nextera XT DNA library prep kit according to the manufacturer’s suggested protocol 
and quantified using a 4200 TapeStation system (Agilent Technologies) and a Qubit dsDNA HS assay kit 
(Thermo Fisher Scientific). Libraries were sequenced on a MiSeq desktop sequencer (Illumina).
Primer ID. Viral RNA was extracted using a QIAamp viral RNA minikit (Qiagen). Primer ID sequencing 
libraries were constructed as previously described (51). In brief, we used the SuperScript III kit (Thermo 
Fisher) with cDNA primers containing a block of degenerate nucleotides (the Primer ID) to synthesize 
cDNA. After bead purification of the cDNA product using RNAClean XP (Beckman), two rounds of PCR 
were performed to incorporate MiSeq sequencing adaptors. Amplified products were purified, pooled, 
and sequenced using Illumina MiSeq 300-bp paired-end sequencing. A detailed protocol can be accessed 
at https://www.protocols.io/view/primer-id-miseq-library-prep-useewbe. We used the Illumina bcl2fastq 
pipeline for the initial data processing and the TCS pipeline (https://github.com/SwanstromLab/PID) to  
construct template consensus sequences.
Data analysis. All data were analyzed with GraphPad Prism software. For viral burden analysis, the 
log-transformed titers were analyzed by a 2-tailed unpaired t test. Viral growth curves were compared by 
2-way analysis of variance (ANOVA) with multiple comparisons. A P value of 0.05 indicated statistically 
significant differences.
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